Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
Type:
Application
Filed:
June 25, 2013
Publication date:
April 28, 2016
Applicant:
SANIONA APS
Inventors:
Janus Schreiber LARSEN, Magnus GUSTAFSSON, Carsten JESSEN
Abstract: Phenyl triazole derivative (specifically, 1-[6-[[5-(2-fluorophenyl)-3-methyl-triazol-4-yl]methoxy]-3-pyridyl]imidazole-4-carbonitrile or a pharmaceutically acceptable salt thereof), pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
Type:
Application
Filed:
November 16, 2015
Publication date:
March 10, 2016
Applicant:
SANIONA APS
Inventors:
Janus Schreiber LARSEN, Magnus GUSTAFSSON, Carsten JESSEN
Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
Type:
Grant
Filed:
June 25, 2013
Date of Patent:
December 8, 2015
Assignee:
SANIONA APS
Inventors:
Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
Abstract: A tetrazole derivative of general formula (I), a pharmaceutical composition comprising said compound and its use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
Type:
Application
Filed:
June 25, 2013
Publication date:
June 4, 2015
Applicant:
SANIONA APS
Inventors:
Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen